Here are the 424B prospectus supplements from Parabilis Medicines, Inc. (PBLS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PBLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBLS filings page.
Parabilis Medicines is registering a primary offering of 33,500,000 shares of voting common stock at an initial public offering price of $20.00 per share. The prospectus states the offering will generate gross proceeds of $670,000,000 and estimated net proceeds to the company of approximately $618.2 million.
The filing discloses a concurrent private placement in which Regeneron has agreed to buy 4,166,666 shares for approximately $75.0 million at a price equal to 90% of the IPO price; that private placement will close concurrently with this offering but the IPO is not contingent on Regeneron’s purchase. Pro forma outstanding shares are presented as 116,564,570 shares immediately after this offering and the concurrent private placement, and 121,589,570 shares if the underwriters’ overallotment is exercised in full.